Tenecteplase: single-bolus thrombolytic therapy for acute myocardial infarction

McGahan L
Record ID 32001000041
English, French
Authors' objectives:

To summarise the available evidence on the use of tenecteplacse single-bolus thrombolytic therapy for acute myocardial infarction.

Authors' recommendations: Tenecteplase is a new fibrin-specific, third generation thrombolytic agent. Health Canada and European authorities are currently reviewing tenecteplase for use in the treatment of acute myocardial infarction (MI). Tenecteplase has received approval for use in the United States. Tenecteplase is the first thrombolytic agent formulated for intravenous needle-less administration over 5 seconds. In clinical trials, 30-day mortality rates were similar in patients who received tenecteplase and those who received the second generation thrombolytic agent, alteplase. However, patients receiving tenecteplase had a lower incidence of non-cerebral bleeding.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Costs and Cost Analysis
  • Fibrinolytic Agents
  • Myocardial Infarction
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.